🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Insiders Buying Pfizer And 2 Other Stocks

Published 10/05/2023, 12:53
Updated 10/05/2023, 14:11
Insiders Buying Pfizer And 2 Other Stocks
PFE
-
LC
-
PFIZ34
-
USBC34
-

Benzinga - Although US stocks closed lower on Tuesday, there were a few notable insider trades.

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

U.S. Bancorp

  • The Trade: U.S. Bancorp (NYSE: USB) Vice Chair James B Kelligrew acquired a total 16,260 shares an average price of $30.60. To acquire these shares, it cost around $497.47 thousand.
  • What’s Happening: Goldman Sachs recently maintained U.S. Bancorp with a Neutral and lowered the price target from $37 to $32.
  • What U.S. Bancorp Does: As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in roughly 26 states, primarily in the Western and Midwestern United States.
LendingClub
  • The Trade: LendingClub Corporation (NYSE: LC) Director Stephen Cutler acquired a total of 14,657 shares at an average price of $6.77. To acquire these shares, it cost around $99.3 thousand.
  • What’s Happening: LendingClub posted better-than-expected quarterly results.
  • What LendingClub Does: LendingClub Corp is a company engaged in operating an online lending marketplace platform that connects borrowers and investors for the provision of the loan facility.
Don’t forget to check out our premarket coverage here

Pfizer

  • The Trade: Pfizer Inc. (NYSE: PFE) Director Scott Gottlieb bought a total of 2,000 shares at an average price of $38.50. To acquire these shares, it cost around $77 thousand.
  • What’s Happening: Pfizer reported a Q1 adjusted EPS of $1.23, down 24% Y/Y, beating the consensus of $0.98.
  • What Pfizer Does: Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales).
Check This Out: Top 5 Financial Stocks That Could Sink Your Portfolio This Quarter

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.